early breast cancer: do we need chemotherapy in low genomic/high clinical risk (er /her2-)?
Published 1 year ago • 179 plays • Length 1:49Download video MP4
Download video MP3
Similar videos
-
1:56
optimizing adjuvant treatment in hr /her2- early breast cancer
-
3:06
prognostic score in early hr /her2- breast cancer: rs, factors, mutations, histology
-
2:44
olympia: adjuvant olaparib in gbrcam, her2-negative, high-risk, early breast cancer
-
40:56
new horizons in high-risk hr her2- ebc: risk stratification for early identification
-
30:56
adjuvant treatment for early stage hormone positive breast cancer: role of genomic signatures
-
3:23
should chemotherapy be used in post-menopausal patients with low genomic risk hr breast cancer?
-
4:33
tailorx: genomic test helps identify low-risk women who do not need chemotherapy
-
8:10
mindact: adjuvant chemotherapy in breast cancer
-
1:22
her2dx risk-score in early-stage her2-positive breast cancer
-
38:22
adjuvant/neoadjuvant therapy for breast cancer: updates and molecular predictors of benefit
-
1:00
defining optimal therapy in high-risk early breast cancer #shorts
-
8:22
molecular profiling in early breast cancer
-
1:01:02
genomic profiling of breast cancer: a multidisciplinary approach in early stage breast cancer...
-
46:31
adjuvant therapy | 2023 best of breast conference
-
14:37
genomic testing in breast cancer: what you must know
-
58:22
adjuvant cdk4 and 6 inhibition to prevent recurrences in high-risk hr /her2- early breast cancer
-
16:07
2021 west oncology | breast cancer | genomic expression panels - esbc chemotherapy decision-making
-
29:21
new advances and opportunities for improvement in hr /her2- early breast cancer
-
2:34
genomic assays impact treatment decisions in patients with er breast cancer